预约演示
Tango Therapeutics’ IND application for TNG260 receives FDA clearance
2023-04-03
临床申请免疫疗法临床研究
TNG260 is a novel, selective inhibitor of the CoREST complex. Credit: Myriams-Fotos from Pixabay.
TNG260Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for TNG260 to treat STK11-mutant cancers.
Tango Therapeuticsn-class inhibitor of the CoREST compFood and Drug Administration (FDA)ment-1 silencing transcription). It is in preclinical deTNG260ent to revSTK11-mutant cancersin STK11 mutated cancers.
Tango Therapeutics president and CEO Dr Barbara Weber said: “FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development oSTK11 mutated cancersSTK11s novel treatment for STK11-mutant cancers. STK11 mutations drive resistance to standard of care immunotherapy, and are a major challenge in treating many cancers, including non-small cell lung cancer.
Tango TherapeuticsG260 will be among the first oncology molecFDAs to leverage the benefits of genetically-based paTNG260selection (STK11-mutation) with checkpoint inhibitor therapy. We look forward to initiatinSTK11-mutant cancersicSTK11ial of TNG260 in the second half of 2023.”cancersnon-small cell lung cancer
The safety, pharTNG260netics, pharmacodynamics and efficacy of TNG260, in combination with pembrolizumab, will be assessed in the pSTK11-mutationcal study.TNG260
The study will cover patients with locally advanced or metastatTNG260cer, or any solid tumopembrolizumabK11 loss-of-function mutation.
The company stated that the combinalocally advanced or metastatic cancerbody enabsolid tumourd completSTK11our regressions in syngeneic models with an STK11 mutation and an intact immune system.
The combination also induced immune memory,TNG260 preventeanti-PD-1 antibodyof the same tumour xenografttumourSTK11
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。